Autosomal dominant DOPA-responsive dystonia (DRD) the mutations caused truncation of the GTPCH I protein. One family carried a base-pair change in the is usually caused by mutation in the gene encoding guanosine triphosphate-cyclohydrolase I (GTPCH I).
Introduction
DOPA-responsive dystonia (DRD) is a disorder characterized levodopa (Segawa et al., 1976 ). An autosomal recessive form of DRD has been described in a few families with by childhood or adolescent onset of dystonia sometimes associated with parkinsonism. Treatment of symptoms is homozygous mutations in the gene encoding tyrosine hydroxylase, the rate-limiting enzyme for dopamine synthesis based on the marked and sustained response to low doses of © Oxford University Press 2000 (Knappskog et al., 1995; Ludecke et al., 1995 Ludecke et al., , 1996 van 
Molecular analysis of the GTP cyclohydrolase I
den Heuvel et al., 1998) . Autosomal dominant DRD, mapped gene to chromosome 14 (Nygaard et al., 1993) , has been shown to
PCR amplification and sequence analysis
be caused by mutations in the gene for guanosine triphosphate All exons and exon-intron junctions of the GTPCH I gene cyclohydrolase I (GTPCH I) (Ichinose et al., 1994) . GTPCH I from 22 index patients were amplified from genomic DNA is the initial and rate-limiting enzyme in the production of by the polymerase chain reaction (PCR) as described by tetrahydrobiopterin, which serves as the cofactor for tyrosine Ichinose and collaborators (Ichinose et al., 1994) , except for hydroxylase.
exon 3, for which a new reverse primer was designed in the Several different mutations in the GTPCH I gene have intronic sequence (5Ј-GATTCTCAGCAGATGAGGG-3Ј). been reported throughout the world (Ichinose et al., 1994;  We also amplified exon 6 of the alternatively spliced type 2 Blau et al., 1995; Hirano et al., 1995; Bandmann et al., GTPCH I (Togari et al., 1992) with primers 5Ј-1996 , 1998 Furukawa et al., 1996; Beyer et al., 1997;  GTGTGATCCATGTAGATGC-3Ј and 5Ј-CGTTGGAC- Illarioshkin et al., 1998) and several studies have ACAGCTCATAATG-3Ј. The 5Ј-untranslated region was demonstrated a dominant negative effect of mutant GTPCH I amplified as described by Bandmann and collaborators on the normal enzyme (Hirano et al., 1996 (Hirano et al., , 1998 Hirano (Bandmann et al., 1998). and Ueno, 1999) . In most families, DRD is an autosomal
The same primers were used for sequencing the PCR dominant disorder with reduced penetrance (~30%) (Nygaard products on both strands using the Big Dye Terminator Cycle et al., 1990) . Female carriers are more often affected than Sequencing Ready Reaction DNA Sequencing Kit (ABI males (3-4 : 1) (Nygaard, 1995) . Homozygous mutations in Prism), according to the manufacturer's recommendations, the GTPCH I gene have also been described; they result in a on an ABI 377 automated sequencer. Sequences were more severe phenotype, resembling atypical phenylketonuria, analysed with the Sequence Analysis 3.0 (ABI Prism) that is not completely responsive to levodopa (Blau et al., software. When a mutation was identified in an index 1995; Furukawa et al., 1998; Hirano and Ueno, 1999) .
case, co-segregation with the disease was established in the Recently, mutations in the parkin gene were found in patient's family. To confirm the presence of the mutation in families with autosomal recessive juvenile parkinsonism relatives or to verify its absence in the control population, PCR Kitada et al., 1998; amplification of genomic DNA was followed by sequence 1998; Abbas et al., 1999) . The phenotype is highly variable, analysis and/or digestion with the appropriate restriction but dystonia with an excellent response to levodopa can endonuclease followed by agarose gel electrophoresis, and/ be the major clinical sign. However, levodopa-induced or polyacrylamide gel electrophoresis. In family SAL-444, dyskinesias are usually precocious and severe in patients mRNA extraction from leucocytes and RT-PCR (reverse with parkin gene mutations as opposed to those with DRD.
transcription-PCR) amplification of the GTPCH I transcript We have sequenced the GTPCH I gene in 22 families was also used. Nucleotide positions were determined with DRD, and have analysed the parkin gene in a according to the cDNA sequence published by Togari and subset of them in order to establish genotype-phenotype collaborators (Togari et al., 1992) (Fig. 1 ). correlations.
Restriction fragment assay

Patients and methods
Twenty-five microlitres of the PCR product were digested with the appropriate restriction enzyme according to the
Families and patients
manufacturer's recommendations and run on a 2% agarose Twenty-two families with dystonia responsive to levodopa gel. in at least one member were selected for molecular analysis. Twenty index cases had the classical DRD phenotype of early-onset dystonia with a complete response to low doses of levodopa. Two additional families were Polyacrylamide gel electrophoresis included after the descendants were found to have classical Two 5Ј-fluorescent (Fam) forward primers (Ichinose et al., DRD: one with spastic paraplegia responsive to levodopa 1994) were used to amplify exon 1 and 6 in the two and one with Parkinson's disease, including levodopafamilies with a small deletion. The presence of the 261-induced dyskinesias in the index cases. Eight cases had 266delGCGGCA variant in exon 1, resulting in a shorter no family history and 14 had at least one affected firstproduct [496 versus 502 base pairs (bp)], and the 631-degree relative. Blood samples were taken with informed 632delAT variant in exon 6, also resulting in a shorter product consent from 33 patients and 40 clinically unaffected first-(233 versus 235 bp), were established by fragment size degree relatives. All families were of French origin except measurement using an ABI 377 automated sequencer one from Algeria. Sixty-four Caucasian subjects with no neurological disorders were included as controls.
with Genescan 3.1 and Genotyper 1.1.1 software (ABI Prism).
mutations, and five had been described previously (Table 1 Extraction of mRNA and RT-PCR and Fig. 1 ). Messenger RNA was extracted from~10 7 lymphocytes of Five non-conservative missense mutations were detected. the index patient with the splice site mutation using the The three new missense mutations ( Fig. 1) were found in QuickPrep Micro mRNA Purification Kit (Pharmacia Biotech, some of the relatives but not on chromosomes from 128 Uppsala, Sweden) and was resuspended in 50 µl water control subjects. after precipitation. Random hexamer primed cDNAs were Two small deletions were identified and verified by synthesized from 8 µl of mRNA in a final volume of 15 µl polyacrylamide gel electrophoresis (Fig. 1) . One, 261-using the First-Strand cDNA Synthesis Kit (Pharmacia 266delGCGGCA(Arg-Gln88-89del), was new, and resulted Biotech). To confirm the splicing of exon 5, we amplified in the deletion of two amino acids. Two nonsense mutations 5 µl of the cDNA reaction using a forward primer (Table 1) , one of which was found in two families and corresponding to a sequence in exon 3 (5Ј-TTCCTone new 538C→T(Gln180Stop) mutation (Fig. 1) , caused ACAAGCAAGTCC-3Ј) and a reverse primer corresponding truncation of the GTPCH I protein. to a sequence in exon 6 (5Ј-AATGCTACTGGCAGT-A splice site mutation (IVS5ϩ1G→A), described ACGATCGG-3Ј). PCRs were performed in a final volume of 25 µl containing 0.5 µM of each primer and 1.25 units of previously (Hirano et al., 1998) , abolished the highly Taq DNA polymerase (Perkin Elmer, Foster City, Calif., conserved consensus sequence GT, which is the splice donor USA). An initial denaturation for 3Ј at 94°C was followed site of intron 5. RT-PCR amplification from exon 3 to exon by 35 cycles of 30 s at 94°C, 30 s at 50°C and 1 min at 6 of the mRNA extracted from lymphocytes showed that all 72°C, with a final extension of 5 min at 72°C. Exon 5 of exon 5 was skipped. Both the normal 334 bp fragment skipping, which resulted in a shorter product (250 versus and a smaller fragment of 250 bp, which does not contain 334 bp), was established by migration on a 2% agarose gel.
the 84 bp corresponding to exon 5, were detected in the DRD patient, whereas the control subject presented only the normal 334 bp band ( Fig. 1 ). This mutation not only deletes exon 5 but also alters the reading frame and creates a
Molecular analysis of the parkin gene
premature stop codon (TAA) at position 215. The entire coding sequence of the parkin gene was tested as Sequence analysis of the 5Ј-untranslated region of the 11 described (Abbas et al., 1999) . In addition, semiquantitative index cases, in whom we had previously failed to find a PCR experiments were used to detect heterozygous deletions mutation in the coding region or the splice sites, revealed a of exons 2-12 (Lücking et al., 2000) .
C→T base change at position -22 in the only patient of one family, but not in 64 controls. When more than one affected subject was available in the family, the specific mutation was present in the affected relative, demonstrating segregation
Statistical analysis
with the disease. Because of reduced penetrance, it was Means were compared by the use of non-parametric tests sometimes also present in unaffected relatives in eight and frequencies with the χ 2 test, with the Yates correction families. However, patient SAL-438-8, who was considered when appropriate.
to be affected but only had brisk reflexes in all the limbs and pain during walking with no spasticity, did not carry the Arg178Ser mutation detected in his relatives.
Results
No mutations in the GTPCH I gene were found in the 10 remaining index cases, seven of which were familial and Molecular analysis three were isolated patients. However, in three of these The entire coding sequence, the exon-intron boundaries, the families, in which the pattern of transmission was compatible 5Ј-untranslated region and the alternatively spliced form of with autosomal recessive inheritance, and where the patients the GTPCH I gene were analysed in 22 index patients with had levodopa-induced dyskinesias, deletions were detected DRD. Eleven different sequence variations were detected in in the parkin gene. Homozygous deletion of exons 8 and 9 the GTPCH I gene in eleven index patients from France and was found in the three patients of family FR-001 (Lucking one from Algeria. Five patients were isolated cases and seven had a family history of DRD. Six had newly identified et al., 1998) . Heterozygous deletion of exons 2 and 3 was Bandmann et al., 1996 observed in the single patient of family SAL-436. The three
Family SAL-609
patients in family SAL-431 carried a heterozygous deletion The 42-year-old mother (SAL-609-7) and her 12-year-old of exon 3 but no point mutation was detected on the other daughter (SAL-609-14), who had gait disorders, were allele after the entire coding region had been sequenced. diagnosed as having spastic paraplegia. The mother had However, considering that the parkin mutation is rare, the suffered from spastic gait since the age of 12 years. On probability that the three patients of family SAL-431 were examination, the gait was broad, reflexes were increased in the all heterozygous carriers by chance is low.
lower limbs and the plantar reflex flexor, and pes cavus and scoliosis were mild. Postural tremor was more pronounced in the upper limbs and predominant in the right hand, EMG was normal, but auditory brainstem-evoked potentials suggested
Clinical features (Table 2) abnormal brainstem conduction. Tremor recordings were In the 12 families with a mutation in the GTPCH I gene, there typical of essential tremor and possibly rest tremor. At age 48 were 27 patients (11 men, 16 women) and 13 asymptomatic years the patient could not walk without a cane and rest tremor carriers (10 men, 3 women), and the female : male ratios in worsened, leading to the introduction of levodopa at age 49 patients and asymptomatic carriers were significantly different years. The treatment caused spectacular remission. The gait (P Ͻ 0.05). The difference between the numbers of became normal after 3 days, but tremor recordings were asymptomatic male and female carriers was also statistically unchanged. It was noticed that the daughter had frequent falls significant (P Ͻ 0.05). Age at examination was 36 Ϯ 19 years and a gait disorder at age 8 years, and she was confined to a and age at onset 16 Ϯ 17 years. Onset occurred earlier in wheelchair at age 13 years. Reflexes were normal, with women (14 Ϯ 15 years) than in men (21 Ϯ 20 years). Two of decreased ankle jerks, the plantar reflex was extensor, and mild the carriers had cramps with increased reflexes in the lower postural tremor in the arms was associated with a dystonic limbs but without functional impairment. In most patients, the writing posture. After introduction of 125 mg levodopa daily initial symptom was a gait disorder (11 out of 23; 48%) or at age 19 years, gait and writer's cramp were alleviated. After abnormal foot posture (seven out of 23; 30%). In two patients, 6 months of levodopa treatment (150 mg/day), both patients tremor was the first sign. Difficulty in writing and torticollis developed typical dyskinesias in the face and choreic were each observed in one patient. Reflexes in the lower limb movements in the upper limbs, but neither complained about were normal in 61% (14 out of 23), increased in 39% (nine out the involuntary movements. of 23), and there was extensor plantar reflex in 26% (six out of 23). The location of the dystonia, the presence of pyramidal signs and the degree of levodopa response (Table 2) were not affected by protein truncation (n ϭ 18) or missense mutation
Family SAL-704
(n ϭ 8). In five patients, dystonia was not prominent; idiopathic Index patient SAL-704-1 was followed for 9 years at the Parkinson's disease had been diagnosed in three and spastic Salpêtrière Hospital in Paris with the diagnosis of familial paraparesis in two.
Parkinson's disease. Autosomal dominant heredity was suspected because a paternal aunt and two of her children had levodopa-responsive parkinsonism, which was confirmed in her cousin, SAL-704-42. Patient SAL-704-1, when examined
Case reports
The following two case reports illustrate some of the diagnostic at age 76 years after 19 years of evolution, showed a symmetrical akinetic-rigid syndrome, with a Unified problems. F ϭ female; M ϭ male; LL ϭ lower limb; UL ϭ upper limb; F ϭ flexor; E ϭ extensor; N ϭ normal; I ϭ increased; ND ϭ not determined; NT ϭ not treated. *Levodopa-induced dyskinesias.
Parkinson's Disease Rating Score of 52 without treatment and and sequelae of stroke. The diagnosis of DRD was proposed only when her two sons, with typical DRD, were examined. 37 with small doses of levodopa. Diphasic dyskinesias were prominent on the left side, and monophasic dyskinesia was
The clinical features of the patients with deletions in the parkin gene are presented in Table 3 . The mean age at onset present in the neck and upper limb. Dementia was evident, with frontal behaviour and a Mini-Mental score of 13/30. At was 17 Ϯ 9 years, which is very similar to that of patients with GTPCH I gene mutations. The phenotype in the three families age 80 years she was confined to a wheelchair, with a fixed flexor posture of the upper limbs and severe dystonic hand included dystonia at onset in five out of seven patients and progressive appearance of parkinsonian signs in all patients. deformations. A brain scan revealed enlarged lateral ventricles F ϭ female; M ϭ male; LL ϭ lower limb; I ϭ increased; F ϭ flexor; N ϭ normal; ND ϭ not determined. *Levodopa-induced dyskinesias.
Levodopa-induced dyskinesias were severe in six out of splice sites has been observed in several families with typical DRD (Bandmann et al., 1996; Ichinose et al., 1994) . Recently, seven patients.
Bandmann and collaborators identified the first mutation in the 5Ј-untranslated region of the GTPCH I gene. This prompted us to extend our sequence analysis to the promoter region in
Discussion
We have reported the screening of 22 families with DOPA-11 mutation-negative families. We found a heterozygous basepair change at position -22 that was different from the change responsive dystonia for mutations in the coding exons, the 5Ј-untranslated region and intron-exon junctions of the GTPCH I reported by Bandmann and collaborators (Bandmann et al., 1998) in a sporadic DRD patient with a typical phenotype. gene. Eleven of the 22 families carried 10 mutations in the coding sequence, which segregated with the disease in all seven
Since it has not been described previously and it was not found in 128 control chromosomes, it cannot represent a frequent kindreds in which at least two affected patients were available. One family had a base change in the 5Ј-untranslated region.
polymorphism. It may interfere with GTPCH I transcription and/or translation. Only five of these mutations have been described previously (Ichinose et al., 1994; Bandmann et al., 1996 Bandmann et al., , 1998 Hirano Mutations in the tyrosine hydroxylase gene also cause DRD but with autosomal recessive inheritance (Knappskog, 1995; et al., 1998) , underlining the large amount of allelic heterogeneity at the GTPCH I locus, which complicates Ludecke et al., 1995 Ludecke et al., , 1996 van den Heuvel et al., 1998) . They cannot, therefore, account for the four families without base molecular diagnosis. Five families carried a single heterozygous missense mutation in the coding region. These changes in the GTPCH I gene, in which transmission of the disease was clearly autosomal dominant. Since most of the mutations were non-conservative, and affected amino acid residues that are highly conserved among species. They are GTPCH I gene, including the exon-6 alternatively spliced form, has been sequenced we cannot exclude the existence of another probably causative mutations as they were not present on 128 control chromosomes. A new 6 bp deletion, affecting two causative gene in DRD. The enzymes involved in the synthesis of tetrahydrobiopterin or dopamine might be good candidates. highly conserved amino acids, was found in a single kindred. Four mutations, in five families, altered the reading frame and
The clinical features of the mutation carriers are highly variable both within and between families. As previously introduced a premature stop codon in the GTPCH I gene. These were a 2 bp deletion, an exon-5 splicing defect and two reported (Nygaard et al., 1990; Ichinose et al., 1994) , there is an excess of women among patients with DRD, and a tendency nonsense mutations.
A common haplotype for four microsatellite markers in the for earlier onset in women than in men. Conversely, there is a significant excess of men among the asymptomatic carriers. In GTPCH I region (D14S978, D14S1057, D14S285, D14S63) segregated with the base change, an Arg216Stop nonsense addition, penetrance is clearly age-dependent in both sexes, which renders genetic counselling difficult. Another problem mutation (data not shown), in two families that live in the same region of France, suggesting that they descend from a single is illustrated by patient SAL-438-8, who had brisk reflexes and pain in the legs when walking, as did several of his affected founder. This mutation has also been reported in a British family (Bandmann et al., 1996) , but the haplotype segregating relatives, some of whom also had spastic gait, but he did not carry the mutation characteristic of the family. Since the with the mutation is unknown.
The absence of a mutation in either the coding region or absence of the Arg178Ser mutation was verified in an independent blood sample, this patient is considered to have a had onset with dystonia, they all subsequently presented parkinsonian signs and all but one had levodopa-induced phenocopy. There were no correlations between the type of mutation and age at onset or clinical presentation. Dystonia dyskinesias. Therefore, the presence of parkinsonism, especially in patients with young onset, and of severe levodopais the most frequent sign in cases with early onset, but its topography might be misleading. Late-onset cases often induced dyskinesias is suggestive of parkin mutations. Our study also shows that the response of DRD to levodopa present with parkinsonism, as did three of our patients, but one of our late-onset cases had dystonia.
is not consistently good. Patient SAL-444-17, who had generalized dystonia, had only a 50% improvement on Symptoms may also be atypical. In family SAL-609, both affected members had early-onset spasticity in the lower limbs, levodopa treatment, whereas the symptoms of his affected relatives were relieved almost completely. Patient SAL-438-6 but the mother also presented postural tremor. They were therefore diagnosed as having a complex form of spastic had only exercise-induced stiffness, but this was not at all responsive to levodopa. It was reported that some patients paraplegia before they were treated with levodopa. Atypical features have also been reported in patients with characterized with dystonia who respond to anticholinergic drugs also carry GTPCH I mutations (Jarman et al., 1997) . This was the case mutations (Table 4) , especially in compound heterozygotes. The presence of levodopa-induced dyskinesias, observed in with patient SAL-37-3, who was initially treated successfully with trihexyphenidyl before the introduction of levodopa. three of the 27 patients in this series who carried a truncating mutation, has not been reported previously, although levodopaThese cases illustrate the importance of a levodopa trial in all patients with dystonia and in cases of spastic paraplegia with induced chorea was described in a woman with athetoid cerebral palsy of unknown origin, which responded severe gait abnormalities and discrete pyramidal signs.
In conclusion, we have identified 11 different mutations in dramatically to the treatment (Fletcher et al., 1993) .
The absence of levodopa-induced dyskinesias is considered the GTPCH I gene, six of which are new, and have confirmed that the mutations can occur in many regions of this gene, to distinguish DRD from autosomal recessive juvenile parkinsonism caused by parkin mutations, as the other including potential regulatory sequences. Our analysis showed that mutations of this gene are responsible for the majority of presentations show considerable overlap. This difference has been explained by the absence of dopaminergic cell loss in DRD cases, especially if autosomal dominant inheritance is present. Most of the mutations occurred in a single patient or the substantia nigra in DRD (Rajput et al., 1994) , where the mutations are thought to cause only dysfunction of the neurons, family, and this, unfortunately, will not facilitate molecular analysis for genetic counselling. Finally, the clinical spectrum as opposed to parkin mutations, which result in marked dopaminergic cell loss in the substantia nigra (Mori et al., associated with these mutations is particularly large and now includes levodopa-induced dyskinesias, introducing the 1998). However, the observation of levodopa-induced dyskinesias in some of the patients with GTPCH I mutations additional diagnostic problem of confusion with patients carrying mutations in the parkin gene. In these cases, only suggests that the nigrostriatal denervation in DRD might affect both pre-and post-synaptic element. Moreover, this study molecular analysis is decisive. included three families in which the index cases presented with dystonic features at onset and progressive parkinsonism but had a marked response to low doses of levodopa. They were
